Archive for the ‘Illumina’ Category

Illumina Inc.

November 25th, 2015 | Posted in 2015, Illumina

As of Nov. 18, San Diego’s Illumina Inc. (Nasdaq: ILMN) is listed on the Standard & Poor’s 500 stock index .

Illumina Inc.

September 5th, 2014 | Posted in 2014, Illumina

Illumina Inc, San Diego, has formed a collaborative partnership with three leading pharmaceutical companies to develop a universal next-generation genetic sequencing tests system for cancers. The partners are AstraZeneca, Sanofi, and Janssen Biotech, a subsidiary of Johnson & Johnson.

Illumina, Inc.

July 30th, 2014 | Posted in 2014, Illumina

Bay Area-based Myraqa, a regulatory and quality consulting firm specializing in IVD, was acquired by Illumina to bolster its in-house capabilities for clinical readiness and help prepare for its next growth phase in regulated markets. Myraqa’s former CEO, Mya Thomae will now report, as VP of Regulatory Affairs, to Illumina’s Chief Medical Officer, Rick Klausner, […]

Illumina Inc

July 18th, 2014 | Posted in 2014, Illumina

Making new inroads into Europe, Illumina Inc has entered into a variety of separate agreements for its non-invasive pre-natal testing products in Germany, Italy and France.

Illumina

April 17th, 2014 | Posted in 2014, Illumina

San Diego-based Illumina announced the sale of its HiSeq X Ten sequencing system to Shangia-based WuXi PharmaTech (Cayman), Inc. WuXi is the only CLIA-certified clinical genomics lab in China.

Illumina

February 18th, 2014 | Posted in 2014, Illumina

Illumina – DNA sequencing giant is setting up what it calls the world’s first genomic incubator.  Named “Illumina Accelerator Program,” the San Diego described the program as a business accelerator to help entrepreneurs and young companies develop uses for next generation sequencing – a market which is dominated by Illumina.

Illumina

February 5th, 2014 | Posted in 2014, Illumina

Illumina– San Diego:  Growing popularity of genomics in research and health care, DNA sequencing leader Illumina reported an increase in revenues and better-than-expected earnings in the 4th quarter, 2013.  Revenues rose 25% to $387-million in the 4th quarter.

Illumina

October 24th, 2013 | Posted in 2013, Illumina

Illumina – San Diego:  A Genetic-Testing equipment maker, recently reported that its net income grew more than 16% in the 3rd quarter on higher product sales.  The company reported a revenue increase of 25% reaching $357-million.

Illumina

October 24th, 2013 | Posted in 2013, Illumina

Illumina – San Diego:  (Nasdaq:  ILMN) Recently announced the launch of its TruGenome Undiagnosed Disease Test provided by the CLIA-Certified, CAP-accredited Illumina Clinical Services Laboratory.  This new service uses whole human genome sequencing to assist physicians identify the genetic cause of a rare or undiagnosed disease.  By providing physicians with more comprehensive information from a […]

Illumina

September 30th, 2013 | Posted in 2013, Illumina

Illumina – Has appointed Dr. Richard Klausner as Senior Vice President SVP and Chief Medical Officer CMO.  Klauser will report to Jay Flatley, President and CEO.